Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOMEC trial of durvalumab and olaparib in advanced endometrial cancer
NL-OMON20492Phase 2Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- May 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and olaparib in endometrial cancer (EC) and endometrial carcinosarcoma, sponsored by Leiden University Medical Center. Primary endpoint: Progression-free survival. Started May 2019; status: active, not recruiting.
02
Drugs
durvalumabolaparib
03
Conditions
endometrial cancer (EC)endometrial carcinosarcoma
Beyond the preview
Go deeper on NL-OMON20492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20492.